Pediatric Liver Transplantation-Liver Fibrosis Evaluation by Using Fibrosis Panel
Condition: Liver Fibrosis · Pediatric Disorder · Liver Transplant; Complications · Sponsor: RenJi Hospital
About this study
Liver transplantation in children is highly successful with \>80% having 20 years survival. Most pediatric liver diseases are potentially curable with liver transplantation and it is important to establish whether children who have undergone successful transplantation can expect a normal life expectancy or whether there will be a gradual decline in liver function and eventual graft loss. The most common reasons in late graft loss in children are unexplained graft inflammation ("idiopathic" post-transplant hepatitis) and graft fibrosis. PRO-C3, a disintegrin and metalloproteinase with thrombospondin motifs-generated neo-epitope marker of type III collagen formation, has been proved to be a marker of fibrosis in patients with NAFLD. The aim of this study is to explore the role of Fibrosis Panel(PRO-C3, PIIINP, TIMP-1, HA) in children received liver transplantation.
This description comes directly from the study's public registry record.
Talk to the study team
Yi ZHOU · 008619921528834 · fenghao@renji.com
Always discuss trial participation with your own doctor first.
Locations (2)
| Deparment of Liver Surgery, Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University | Shanghai, China | Recruiting |
| Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University | Shanghai, China | Not Yet Recruiting |
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05308628